Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

V. Rouillé · SciRah

Researcher profile · Semantic Scholar

V. Rouillé

Share profile

V. Rouillé — researcher profile on SciRah

h-index: 11
Works: 29
Citations: 383

Most-cited papers

Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study
J. Rossi, J. Moreaux, D. Hose, G. Requirand +7 more
2009British Journal of Cancer83 citations Open access
Semantic Scholar
Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study.
G. Cartron, Zhao-Yang Lu, M. Baudard, T. Kanouni +4 more
2008Journal of Clinical Oncology76 citations Open access
Semantic Scholar
Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects
J. Rossi, N. Fégueux, Zhao-Yang Lu, E. Legouffe +10 more
2005Bone Marrow Transplantation63 citations Open access
Semantic Scholar
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia
R. Letestu, Abdelmalek Dahmani, M. Boubaya, L. Baseggio +25 more
2020Leukemia24 citations Open access
Semantic Scholar
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
A. Michallet, M. Dilhuydy, F. Subtil, V. Rouillé +30 more
2019The Lancet Haematology20 citations Open access
Semantic Scholar
Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial
Romain Guièze, Loïc Ysebaert, Damien Roos-Weil, L. Fornecker +24 more
2024Nature Communications13 citations Open access
Semantic Scholar
Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group
R. Guièze, L. Ysebaert, D. Roos-Weil, L. Fornecker +18 more
2022Blood13 citations
Semantic Scholar
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
A. Michallet, R. Letestu, M. Le Garff-Tavernier, C. Aanei +30 more
2020Blood12 citations Open access
Semantic Scholar
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial
A. Michallet, R. Letestu, M. Le Garff-Tavernier, L. Campos +29 more
2023Blood Advances11 citations Open access
Semantic Scholar
Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial
M. Hunault-Berger, N. Maillard, C. Himberlin, C. Récher +27 more
2017Blood Cancer Journal11 citations Open access
Semantic Scholar
Rituximab Activity Is Potentiated by GM-CSF in Patients with Relapsed, Follicular Lymphoma: Results of a Phase II Study.
J. Rossi, Zao-Yang Lu, P. Quittet, M. Baudard +2 more
200511 citations
Semantic Scholar
Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study
G. Cartron, R. Letestu, C. Dartigeas, M. Tout +18 more
2018Haematologica10 citations Open access
Semantic Scholar
Blinatumomab for Patients with Richter's Syndrome: A Multicenter Phase 2 Trial from the Filo Group
R. Guièze, L. Ysebaert, D. Roos-Weil, L. Molina +18 more
2021Blood8 citations Open access
Semantic Scholar
Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group
A. Michallet, R. Letestu, M. Legarff, S. Morisset +30 more
2024Blood5 citations
Semantic Scholar
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group
A. Quinquenel, R. Letestu, M. Le Garff-Tavernier, Stéphane Morisset +38 more
2025EClinicalMedicine4 citations Open access
Semantic Scholar
Phase II, Multicenter Trial, Exploring "Chemo-Sparing" Strategy Associating Obinutuzumab+Ibrutinib Followed By a MRD Driven Strategy, in Previously Untreated Symptomatic Medically Fit Chronic Lymphocytic Leukemia Patients (CLL): Preliminary Results of the Induction Phase of the Icll-07 Filo Study
A. Michallet, M. Dilhuydy, F. Subtil, V. Rouillé +29 more
20174 citations
Semantic Scholar
Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR
A. Michallet, A. Quinquenel, R. Letestu, M. Le Garff-Tavernier +36 more
2021Blood3 citations Open access
Semantic Scholar
Safety and Long-Term Efficacy of Maintenance Therapy with Alternating Azacytidine (AZA) and Lenalidomide (Len) Cycles in Elderly (≥ 60) Fit Patients (Pts) with Poor Prognosis AML in First Complete Remission (CR) After LIA Induction. A Phase II Multicentric GOELAMS Trial
M. Hunault, Nathalie Maillard, A. Tanguy-Schmidt, C. Himberlin +26 more
20153 citations
Semantic Scholar
Blinatumomab after R-CHOP Debulking Therapy for Patients with Richter Transformation: Preliminary Results of the Multicenter Phase 2 Blinart Trial from the Filo Group
R. Guièze, L. Ysebaert, L. Molina, D. Roos-Weil +10 more
20202 citations Open access
Semantic Scholar
Maintenance Therapy With Alternating Azacytidine and Lenalidomide Cycles In Elderly (≥ 60) Fit Patients (Pts) With Poor Prognosis AML In First Complete Remission (CR) After Lia Induction. A Phase II Multicentric Goelams Trial
M. Hunault-Berger, Edouard Randriamalala, A. schmidt-Tanguy, C. Himberlin +26 more
20132 citations
Semantic Scholar
Time-limited acalabrutinib monotherapy in frail patients with previously untreated chronic lymphocytic leukemia: Primary endpoint analysis of the randomized STAIR trial.
R. Guièze, E. Ferrant, F. Merabet, Lysiane Molina +30 more
2025Blood1 citations
Semantic Scholar
Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation
A. Quinquenel, R. Letestu, M. Le Garff-Tavernier, F. Subtil +35 more
2022Blood1 citations Open access
Semantic Scholar
High Rate of Complete Response (CR) with Undetectable Bone Marrow Minimal Residual Disease (MRD) after Chemo-Sparing and MRD-Driven Strategy for Untreated Fit CLL Patients: Final Results of the Icll 07 Filo Trial
A. Michallet, M. Dilhuydy, F. Subtil, V. Rouillé +29 more
2018Blood1 citations
Semantic Scholar
Efficient Vaccination of Follicular Lymphoma (FL) Patients with Multiple Intradermal (ID) and Intravenous (IV) Administrations of Mature Dendritic Cells (DC) Loaded with Tumor Cell Lysate Ex Vivo.
J. Rossi, M. Baudard, A. Conge, F. Comte +6 more
20051 citations
Semantic Scholar
A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 icll-07 filo trial
A. Michallet, R. Letestu, M. Le Garff-Tavernier, Lydia Campos +25 more
2025Blood0 citations
Semantic Scholar
Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group
A. Michallet, A. Quinquenel, R. Letestu, Tavernier Magali +35 more
2023Blood0 citations Open access
Semantic Scholar
A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial
A. Michallet, R. Letestu, M. Le Garff-Tavernier, Carmen Aanaei +30 more
2022Blood0 citations Open access
Semantic Scholar
Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial
A. Michallet, M. Dilhuydy, F. Subtil, V. Rouillé +30 more
2019Blood0 citations Open access
Semantic Scholar
Phase I Study of IPH1101 (with Low Dose of IL-2) in Patient with B-NHL
J. Rossi, V. Rouillé, Sylvie Lafaye de Micheaux, H. Sicard +4 more
20080 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Michallet×18
Invite
A. Michallet — researcher profile on SciRah
S. de Guibert×18
Invite
S. de Guibert — researcher profile on SciRah
K. Laribi×17
Invite
K. Laribi — researcher profile on SciRah
L. Fornecker×17
Invite
L. Fornecker — researcher profile on SciRah

×16

Invite

S. Leprêtre — researcher profile on SciRah

Invite

R. Letestu — researcher profile on SciRah

C. Dartigeas×15

Invite

C. Dartigeas — researcher profile on SciRah

O. Tournilhac×15

Invite

O. Tournilhac — researcher profile on SciRah

Invite

A. Delmer — researcher profile on SciRah

Invite

P. Feugier — researcher profile on SciRah

Invite

G. Cartron — researcher profile on SciRah

M. Dilhuydy×14

Invite

M. Dilhuydy — researcher profile on SciRah